GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pasithea Therapeutics Corp (NAS:KTTA) » Definitions » Cost of Goods Sold

Pasithea Therapeutics (Pasithea Therapeutics) Cost of Goods Sold : $0.00 Mil (TTM As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Pasithea Therapeutics Cost of Goods Sold?

Pasithea Therapeutics's cost of goods sold for the three months ended in Mar. 2024 was $0.00 Mil. Its cost of goods sold for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Pasithea Therapeutics's Gross Margin % for the three months ended in Mar. 2024 was %.

Cost of Goods Sold is also directly linked to Inventory Turnover.


Pasithea Therapeutics Cost of Goods Sold Historical Data

The historical data trend for Pasithea Therapeutics's Cost of Goods Sold can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pasithea Therapeutics Cost of Goods Sold Chart

Pasithea Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Cost of Goods Sold
- 0.02 -0.37 -

Pasithea Therapeutics Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cost of Goods Sold Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Pasithea Therapeutics Cost of Goods Sold Calculation

Cost of Goods Sold is the aggregate cost of goods produced and sold, and services rendered during the reporting period. It excludes Total Operating Expense, such as Depreciation, Depletion and Amortization and Selling, General, & Admin. Expense.

Cost of Goods Sold for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pasithea Therapeutics  (NAS:KTTA) Cost of Goods Sold Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Pasithea Therapeutics's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Cost of Goods Sold is also directly linked to another concept called Inventory Turnover:

Pasithea Therapeutics's Inventory Turnover for the three months ended in Mar. 2024 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher inventory turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate inventory turnover. An average inventory is a better indication.


Pasithea Therapeutics Cost of Goods Sold Related Terms

Thank you for viewing the detailed overview of Pasithea Therapeutics's Cost of Goods Sold provided by GuruFocus.com. Please click on the following links to see related term pages.


Pasithea Therapeutics (Pasithea Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
1111 Lincoln Road, Suite 500, Miami Beach, FL, USA, 33139
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders. Epidemiological data indicate neuropsychiatric disorders as being some of the most prevalent, devastating, and yet poorly treated illnesses.
Executives
Graeme Martin Currie officer: Chief Development Officer 51 BARBAREE WAY, TIBURON CA 94920
Lawrence Steinman director 10555 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121
Bradford Manning 10 percent owner C/O PBM CAPITAL GROUP, LLC, 200 GARRETT STREET, SUITE S, CHARLOTTESVILLE VA 22902
Paul B Manning 10 percent owner 200 GARRETT STREET SUITE S, CHARLOTTESVILLE VA 22902
Tiger Lily Capital, Llc 10 percent owner C/O PBM CAPITAL GROUP, LLC, 200 GARRETT STREET, SUITE S, CHARLOTTESVILLE VA 22902
Pd Joint Holdings, Llc Series 2016-a 10 percent owner C/O TIGER LILY CAPITAL LLC, 200 GARRETT STREET, SUITE O, CHARLOTTESVILLE VA 22902
Elderhill Corp other: Member of 10% owner group C/O CONCORD INVESTMENT PARTNERS LTD., 60 ST. CLAIR AVENUE EAST, SUITE 702, TORONTO A6 M4T IN5
Concord Ip2 Ltd. other: Member of 10% owner group C/O CONCORD INVESTMENT PARTNERS LTD., 60 ST. CLAIR AVENUE EAST, SUITE 702, TORONTO A6 M4T 1N5
David Delaney other: Member of 10% owner group C/O CONCORD INVESTMENT PARTNERS LTD., 60 ST. CLAIR AVENUE EAST, SUITE 702, TORONTO A6 M4T 1N5
Eric Shahinian other: Member of 10% owner group 350 PARK AVE, 13TH FL, NEW YORK NY 10022
Alfred J Novak director 325 NE 6TH ST, BOCA RATON FL 33432
Camac Partners, Llc other: Member of 10% owner group 350 PARK AVENUE, 13TH FLOOR, NEW YORK NY 10022
Camac Capital, Llc other: Member of 10% owner group 350 PARK AVENUE, 13TH FLOOR, NEW YORK NY 10022
Camac Fund, Lp other: Member of 10% owner group CAMAC CAPITAL, LLC, 350 PARK AVENUE, 13TH FLOOR, NEW YORK NY 10022
Leonite Capital Llc other: Member of 10% owner group 1 HILLCREST CENTER DR., SUITE 232, SPRING VALLEY NY 10977

Pasithea Therapeutics (Pasithea Therapeutics) Headlines